Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation

Thyroid ◽  
2017 ◽  
Vol 27 (4) ◽  
pp. 531-536 ◽  
Author(s):  
Feng-Chih Shen ◽  
Ching-Jung Hsieh ◽  
I-Chin Huang ◽  
Yen-Hsiang Chang ◽  
Pei-Wen Wang
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Chinese Patients ◽  
Remnant Ablation ◽  
Dynamic Risk ◽  
Risk Estimates ◽  
Well Differentiated

scholarly journals A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer

2004 ◽  
Vol 89 (8) ◽  
pp. 3668-3676 ◽  
Author(s):  
Anna M. Sawka ◽  
Kullathorn Thephamongkhol ◽  
Melissa Brouwers ◽  
Lehana Thabane ◽  
George Browman ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Remnant Ablation ◽  
Well Differentiated

scholarly journals Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine

2016 ◽  
Vol 101 (7) ◽  
pp. 2692-2700 ◽  
Author(s):  
Denise P. Momesso ◽  
Fernanda Vaisman ◽  
Samantha P. Yang ◽  
Daniel A. Bulzico ◽  
Rossana Corbo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Risk Stratification ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Response To Therapy ◽  
Therapy Assessment ◽  
Dynamic Risk ◽  
Incomplete Response ◽  
Risk Estimates ◽  
Negative Imaging

Context: Although response to therapy assessment is a validated tool for dynamic risk stratification in patients with differentiated thyroid cancer (DTC) treated with total thyroidectomy (TT) and radioactive iodine therapy (RAI), it has not been well studied in patients treated with lobectomy or TT without RAI. Because these responses to therapy definitions are heavily dependent on serum thyroglobulin (Tg) levels, modifications of the original definitions were needed to appropriately classify patients treated without RAI. Objective: This study aimed to validate the response to therapy assessment in patients with DTC treated with lobectomy or TT without RAI. Design and Setting: This was a retrospective study, which took place at a referral center. Patients: A total of 507 adults with DTC were treated with lobectomy (n = 187) or TT (n = 320) without RAI. They had a median age of 43.7 y, 88% were female, 85.4% had low risk, and 14.6% intermediate risk. Main Outcome Measure: Main outcome measured was recurrent/persistent structural evidence of disease (SED) during a median followup period of 100.5 months (24–510). Results: Recurrent/persistent SED was observed in 0% of the patients with excellent response to therapy (nonstimulated Tg for TT < 0.2 ng/mL and for lobectomy < 30 ng/mL, undetectable Tg antibodies [TgAb] and negative imaging; n = 326); 1.3% with indeterminate response (nonstimulated Tg for TT 0.2–5 ng/mL, stable or declining TgAb and/or nonspecific imaging findings; n = 2/152); 31.6% of the patients with biochemical incomplete response (nonstimulated Tg for TT > 5 ng/mL and for lobectomy > 30 ng/mL and/or increasing Tg with similar TSH levels and/or increasing TgAb and negative imaging; n = 6/19) and all (100%) patients with structural incomplete response (n = 10/10) (P < .0001). Initial American Thyroid Association risk estimates were significantly modified based on response to therapy assessment. Conclusions: Our data validate the newly proposed response to therapy assessment in patients with DTC treated with lobectomy or TT without RAI as an effective tool to modify initial risk estimates of recurrent/persistent SED and better tailor followup and future therapeutic approaches. This study provides further evidence to support a selective use of RAI in DTC.

Sign in / Sign up

Export Citation Format

Share Document